Search

Your search keyword '"Masur, Henry"' showing total 1,459 results
Start Over Author "Masur, Henry"

Refine your results

1,459 results on '"Masur, Henry"'

3. Characterization of HIV Risk Behaviors and Clusters Using HIV-Transmission Cluster Engine Among a Cohort of Persons Living with HIV in Washington, DC

Author

Wilbourn, Brittany, Saafir-Callaway, Brittani, Jair, Kamwing, Wertheim, Joel O, Laeyendeker, Oliver, Jordan, Jeanne A, Kharfen, Michael, Castel, Amanda, D'Angelo, Lawrence, Rakhmanina, Natella, Serlin, Michael, Kumar, Princy, Bamdad, Aria, Bezabeh, Tsedenia, Reamer, Susan, Sapozhnikova, Alla, Temprosa, Marinella, Younes, Naji, Liu, Jinxi, Xiao, Kevin, Byrne, Morgan, Greenberg, Alan, Jaurretche, Maria, Levy, Matthew, Monroe, Anne, Peterson, James, Happ, Lindsey Powers, Jordan, Jeanne, Ma, Yan, Akselrod, Hana, Wilcox, Ronald, Rana, Sohail, Horberg, Michael, Fernandez, Ricardo, Hebou, Annick, Dieffenbach, Carl, Masur, Henry, Bordon, Jose, Teferi, Gebeyehu, Benator, Debra, Ruiz, Maria Elena, and Abbott, Stephen

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Behavioral and Social Science, HIV/AIDS, Prevention, Infectious Diseases, Infection, Good Health and Well Being, District of Columbia, Epidemics, HIV Infections, Humans, Molecular Epidemiology, Risk-Taking, United States, HIV, molecular epidemiology, HIV clusters, HIV-TRACE, DC Cohort Executive Committee, Virology, Clinical sciences
Abstract

Molecular epidemiology (ME) is one tool used to end the HIV epidemic in the United States. We combined clinical and behavioral data with HIV sequence data to identify any overlap in clusters generated from different sequence datasets; to characterize HIV transmission clusters; and to identify correlates of clustering among people living with HIV (PLWH) in Washington, District of Columbia (DC). First, Sanger sequences from DC Cohort participants, a longitudinal HIV study, were combined with next-generation sequences (NGS) from participants in a ME substudy to identify clusters. Next, demographic and self-reported behavioral data from ME substudy participants were used to identify risks of secondary transmission. Finally, we combined NGS from ME substudy participants with Sanger sequences in the DC Molecular HIV Surveillance database to identify clusters. Cluster analyses used HIV-Transmission Cluster Engine to identify linked pairs of sequences (defined as distance ≤1.5%). Twenty-eight clusters of ≥3 sequences (size range: 3-12) representing 108 (3%) participants were identified. None of the five largest clusters (size range: 5-12) included newly diagnosed PLWH. Thirty-four percent of ME substudy participants (n = 213) reported condomless sex during their last sexual encounter and 14% reported a Syphilis diagnosis in the past year. Seven transmission clusters (size range: 2-19) were identified in the final analysis, each containing at least one ME substudy participant. Substudy participants in clusters from the third analysis were present in clusters from the first analysis. Combining HIV sequence, clinical and behavioral data provided insights into HIV transmission that may not be identified using traditional epidemiological methods alone. Specifically, the sexual risk behaviors and STI diagnoses reported in the substudy survey may not have been disclosed during Partner Services activities and the survey data complemented clinical data to fully characterize transmission clusters. These findings can be used to enhance local efforts to interrupt transmission and avert new infections.

Published
2021

4. Developing Treatment Guidelines During a Pandemic Health Crisis: Lessons Learned From COVID-19

Author

Kuriakose, Safia, Singh, Kanal, Pau, Alice K, Daar, Eric, Gandhi, Rajesh, Tebas, Pablo, Evans, Laura, Gulick, Roy M, Lane, H Clifford, Masur, Henry, Aberg, Judith A, Adimora, Adaora A, Baker, Jason, Kreuziger, Lisa Baumann, Bedimo, Roger, Belperio, Pamela S, Cantrill, Stephen V, Coopersmith, Craig M, Davis, Susan L, Dzierba, Amy L, Gallagher, John J, Glidden, David V, Grund, Birgit, Hardy, Erica J, Hinkson, Carl, Hughes, Brenna L, Johnson, Steven, Keller, Marla J, Kim, Arthur Y, Lennox, Jeffrey L, Levy, Mitchell M, Li, Jonathan Z, Martin, Greg S, Naggie, Susanna, Pavia, Andrew T, Seam, Nitin, Simpson, Steven Q, Swindells, Susan, Tien, Phyllis, Waghmare, Alpana A, Wilson, Kevin C, Yazdany, Jinoos, Zachariah, Philip, Campbell, Danielle M, Harrison, Carly, Burgess, Timothy, Francis, Joseph, Sheikh, Virginia, Uyeki, Timothy M, Walker, Robert, Brooks, John T, Ortiz, Laura Bosque, Davey, Richard T, Doepel, Laurie K, Eisinger, Robert W, Han, Alison, Higgs, Elizabeth S, Nason, Martha C, Crew, Page, Lerner, Andrea M, Lund, Claire, and Worthington, Christopher

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Health Services, Clinical Research, Generic health relevance, Good Health and Well Being, Advisory Committees, COVID-19, Child, Data Interpretation, Statistical, Drug Approval, Evidence-Based Medicine, Female, Humans, Interprofessional Relations, National Institutes of Health (U.S.), Pandemics, Practice Guidelines as Topic, Pregnancy, SARS-CoV-2, Stakeholder Participation, United States, COVID-19 Drug Treatment, NIH COVID-19 Treatment Guidelines Panel, Medical and Health Sciences, General & Internal Medicine, Clinical sciences
Abstract

The development of the National Institutes of Health (NIH) COVID-19 Treatment Guidelines began in March 2020 in response to a request from the White House Coronavirus Task Force. Within 4 days of the request, the NIH COVID-19 Treatment Guidelines Panel was established and the first meeting took place (virtually-as did subsequent meetings). The Panel comprises 57 individuals representing 6 governmental agencies, 11 professional societies, and 33 medical centers, plus 2 community members, who have worked together to create and frequently update the guidelines on the basis of evidence from the most recent clinical studies available. The initial version of the guidelines was completed within 2 weeks and posted online on 21 April 2020. Initially, sparse evidence was available to guide COVID-19 treatment recommendations. However, treatment data rapidly accrued based on results from clinical studies that used various study designs and evaluated different therapeutic agents and approaches. Data have continued to evolve at a rapid pace, leading to 24 revisions and updates of the guidelines in the first year. This process has provided important lessons for responding to an unprecedented public health emergency: Providers and stakeholders are eager to access credible, current treatment guidelines; governmental agencies, professional societies, and health care leaders can work together effectively and expeditiously; panelists from various disciplines, including biostatistics, are important for quickly developing well-informed recommendations; well-powered randomized clinical trials continue to provide the most compelling evidence to guide treatment recommendations; treatment recommendations need to be developed in a confidential setting free from external pressures; development of a user-friendly, web-based format for communicating with health care providers requires substantial administrative support; and frequent updates are necessary as clinical evidence rapidly emerges.

Published
2021

5. Infectious Diseases Society of America Position Paper: Recommended Revisions to the National Severe Sepsis and Septic Shock Early Management Bundle (SEP-1) Sepsis Quality Measure

Author

Rhee, Chanu, Chiotos, Kathleen, Cosgrove, Sara E, Heil, Emily L, Kadri, Sameer S, Kalil, Andre C, Gilbert, David N, Masur, Henry, Septimus, Edward J, Sweeney, Daniel A, Strich, Jeffrey R, Winslow, Dean L, and Klompas, Michael

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Sepsis, Hematology, Prevention, Infectious Diseases, Infection, Inflammatory and immune system, Good Health and Well Being, Aged, Anti-Bacterial Agents, Communicable Diseases, Humans, Medicare, Quality Indicators, Health Care, Reproducibility of Results, Shock, Septic, United States, sepsis, septic shock, SEP-1, severe sepsis, IDSA, Biological Sciences, Medical and Health Sciences, Microbiology, Clinical sciences
Abstract

The Centers for Medicare & Medicaid Services' Severe Sepsis and Septic Shock Early Management Bundle (SEP-1) measure has appropriately established sepsis as a national priority. However, the Infectious Diseases Society of America (IDSA and five additional endorsing societies) is concerned about SEP-1's potential to drive antibiotic overuse because it does not account for the high rate of sepsis overdiagnosis and encourages aggressive antibiotics for all patients with possible sepsis, regardless of the certainty of diagnosis or severity of illness. IDSA is also concerned that SEP-1's complex "time zero" definition is not evidence-based and is prone to inter-observer variation. In this position paper, IDSA outlines several recommendations aimed at reducing the risk of unintended consequences of SEP-1 while maintaining focus on its evidence-based elements. IDSA's core recommendation is to limit SEP-1 to septic shock, for which the evidence supporting the benefit of immediate antibiotics is greatest. Prompt empiric antibiotics are often appropriate for suspected sepsis without shock, but IDSA believes there is too much heterogeneity and difficulty defining this population, uncertainty about the presence of infection, and insufficient data on the necessity of immediate antibiotics to support a mandatory treatment standard for all patients in this category. IDSA believes guidance on managing possible sepsis without shock is more appropriate for guidelines that can delineate the strengths and limitations of supporting evidence and allow clinicians discretion in applying specific recommendations to individual patients. Removing sepsis without shock from SEP-1 will mitigate the risk of unnecessary antibiotic prescribing for noninfectious syndromes, simplify data abstraction, increase measure reliability, and focus attention on the population most likely to benefit from immediate empiric broad-spectrum antibiotics.

Published
2021

6. Convalescent Plasma for the Treatment of COVID-19: Perspectives of the National Institutes of Health COVID-19 Treatment Guidelines Panel

Author

Pau, Alice K, Aberg, Judith, Baker, Jason, Belperio, Pamela S, Coopersmith, Craig, Crew, Page, Glidden, David V, Grund, Birgit, Gulick, Roy M, Harrison, Carly, Kim, Arthur, Lane, H Clifford, Masur, Henry, Sheikh, Virginia, Singh, Kanal, Yazdany, Jinoos, and Tebas, Pablo

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Clinical Research, Emerging Infectious Diseases, Clinical Trials and Supportive Activities, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Good Health and Well Being, COVID-19, Humans, Immunization, Passive, National Institutes of Health (U.S.), Plasma, SARS-CoV-2, United States, COVID-19 Serotherapy, National Institutes of Health COVID-19 Treatment Guidelines Panel, Medical and Health Sciences, General & Internal Medicine, Clinical sciences
Abstract

In the United States, the efficacy and safety of convalescent plasma for treating coronavirus disease 2019 (COVID-19) is currently being tested in randomized placebo-controlled clinical trials. Treatment of individual patients with COVID-19 with convalescent plasma outside such trials is also now permitted through U.S. Food and Drug Administration Emergency Use Authorization. Here, members of the National Institutes of Health COVID-19 Treatment Guidelines Panel provide their views regarding use of convalescent plasma for treating COVID-19.

Published
2021

7. Flow-Sizing Critical Care Resources*

Author

Nates, Joseph L., Oropello, John M., Badjatia, Neeraj, Beilman, Gregory, Coopersmith, Craig M., Halpern, Neil A., Herr, Daniel L., Jacobi, Judith, Kahn, Roozehra, Leung, Sharon, Puri, Nitin, Sen, Ayan, Pastores, Stephen M., Angus, Derek C., Baker, Andrew, Brown, Daniel R., Buchman, Timothy S., Christman, John W., Cobb, J. Perren, D’Agostino, Rhonda, Diaz-Gomez, Jose, Doig, Christopher, Farmer, J. Christopher, Galvagno, Samuel M., Gasperino, James, Gregg, Sara R., Kaiser, Eric, Kapu, April N., Khouli, Hassan, Kohli-Seth, Roopa, Laussen, Peter, Lilly, Craig M., Marinaro, Jon, Masur, Henry, Mehta, Gargi, Melander, Sheila, Moore, Jason, Popovich, Marc, Price, Kristen, Rahmanian, Marjan, and Sessler, Curtis

Published
2023
Full Text
View/download PDF

8. Undertreatment of opioid use disorder in patients hospitalized with injection drug use-associated infections

Author

Rosenthal, Elana S., Brokus, Christopher, Sun, Junfeng, Carpenter, Joseph E., Catalanotti, Jillian, Eaton, Ellen F., Steck, Alaina R., Kuo, Irene, Burkholder, Greer A., Akselrod, Hana, McGonigle, Keanan, Moran, Timothy, Mai, William, Notis, Melissa, Del Rio, Carlos, Greenberg, Alan, Saag, Michael S., Kottilil, Shyamasundaran, Masur, Henry, and Kattakuzhy, Sarah

Published
2023
Full Text
View/download PDF

9. Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium

Author

Donnelly, J Peter, Chen, Sharon C, Kauffman, Carol A, Steinbach, William J, Baddley, John W, Verweij, Paul E, Clancy, Cornelius J, Wingard, John R, Lockhart, Shawn R, Groll, Andreas H, Sorrell, Tania C, Bassetti, Matteo, Akan, Hamdi, Alexander, Barbara D, Andes, David, Azoulay, Elie, Bialek, Ralf, Bradsher, Robert W, Bretagne, Stephane, Calandra, Thierry, Caliendo, Angela M, Castagnola, Elio, Cruciani, Mario, Cuenca-Estrella, Manuel, Decker, Catherine F, Desai, Sujal R, Fisher, Brian, Harrison, Thomas, Heussel, Claus Peter, Jensen, Henrik E, Kibbler, Christopher C, Kontoyiannis, Dimitrios P, Kullberg, Bart-Jan, Lagrou, Katrien, Lamoth, Frédéric, Lehrnbecher, Thomas, Loeffler, Jurgen, Lortholary, Olivier, Maertens, Johan, Marchetti, Oscar, Marr, Kieren A, Masur, Henry, Meis, Jacques F, Morrisey, C Orla, Nucci, Marcio, Ostrosky-Zeichner, Luis, Pagano, Livio, Patterson, Thomas F, Perfect, John R, Racil, Zdenek, Roilides, Emmanuel, Ruhnke, Marcus, Prokop, Cornelia Schaefer, Shoham, Shmuel, Slavin, Monica A, Stevens, David A, Thompson, George R, Vazquez, Jose A, Viscoli, Claudio, Walsh, Thomas J, Warris, Adilia, Wheat, L Joseph, White, P Lewis, Zaoutis, Theoklis E, and Pappas, Peter G

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Cancer, Prevention, Clinical Research, Good Health and Well Being, Antifungal Agents, Consensus, Humans, Immunocompromised Host, Invasive Fungal Infections, Mycoses, Neoplasms, consensus, definitions, invasive fungal diseases, diagnosis, research, Biological Sciences, Medical and Health Sciences, Microbiology, Clinical sciences
Abstract

BackgroundInvasive fungal diseases (IFDs) remain important causes of morbidity and mortality. The consensus definitions of the Infectious Diseases Group of the European Organization for Research and Treatment of Cancer and the Mycoses Study Group have been of immense value to researchers who conduct clinical trials of antifungals, assess diagnostic tests, and undertake epidemiologic studies. However, their utility has not extended beyond patients with cancer or recipients of stem cell or solid organ transplants. With newer diagnostic techniques available, it was clear that an update of these definitions was essential.MethodsTo achieve this, 10 working groups looked closely at imaging, laboratory diagnosis, and special populations at risk of IFD. A final version of the manuscript was agreed upon after the groups' findings were presented at a scientific symposium and after a 3-month period for public comment. There were several rounds of discussion before a final version of the manuscript was approved.ResultsThere is no change in the classifications of "proven," "probable," and "possible" IFD, although the definition of "probable" has been expanded and the scope of the category "possible" has been diminished. The category of proven IFD can apply to any patient, regardless of whether the patient is immunocompromised. The probable and possible categories are proposed for immunocompromised patients only, except for endemic mycoses.ConclusionsThese updated definitions of IFDs should prove applicable in clinical, diagnostic, and epidemiologic research of a broader range of patients at high-risk.

Published
2020

10. Error, Fraud, and Responsibility

Author

Buchman, Timothy G., Bleck, Thomas P., Busl, Katharina M., Dellinger, R. Phillip, Deutschman, Clifford S., Kadri, Sameer S., Marshall, John C., Maslove, David M., Masur, Henry, Osborn, Tiffany M., Parker, Margaret M., Rochwerg, Bram, Sarwal, Aarti, Sevransky, Jonathan E., and Thiagarajan, Ravi R.

Published
2023
Full Text
View/download PDF

11. Surviving Sepsis Campaign

Author

Dellinger, R. Phillip, Rhodes, Andrew, Evans, Laura, Alhazzani, Waleed, Beale, Richard, Jaeschke, Roman, Machado, Flavia R., Masur, Henry, Osborn, Tiffany, Parker, Margaret M., Schorr, Christa, Townsend, Sean R., and Levy, Mitchell M.

Published
2023
Full Text
View/download PDF

12. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021

Author

Evans, Laura, Rhodes, Andrew, Alhazzani, Waleed, Antonelli, Massimo, Coopersmith, Craig M., French, Craig, Machado, Flávia R., Mcintyre, Lauralyn, Ostermann, Marlies, Prescott, Hallie C., Schorr, Christa, Simpson, Steven, Wiersinga, W. Joost, Alshamsi, Fayez, Angus, Derek C., Arabi, Yaseen, Azevedo, Luciano, Beale, Richard, Beilman, Gregory, Belley-Cote, Emilie, Burry, Lisa, Cecconi, Maurizio, Centofanti, John, Coz Yataco, Angel, De Waele, Jan, Dellinger, R. Phillip, Doi, Kent, Du, Bin, Estenssoro, Elisa, Ferrer, Ricard, Gomersall, Charles, Hodgson, Carol, Møller, Morten Hylander, Iwashyna, Theodore, Jacob, Shevin, Kleinpell, Ruth, Klompas, Michael, Koh, Younsuck, Kumar, Anand, Kwizera, Arthur, Lobo, Suzana, Masur, Henry, McGloughlin, Steven, Mehta, Sangeeta, Mehta, Yatin, Mer, Mervyn, Nunnally, Mark, Oczkowski, Simon, Osborn, Tiffany, Papathanassoglou, Elizabeth, Perner, Anders, Puskarich, Michael, Roberts, Jason, Schweickert, William, Seckel, Maureen, Sevransky, Jonathan, Sprung, Charles L., Welte, Tobias, Zimmerman, Janice, and Levy, Mitchell

Published
2021
Full Text
View/download PDF

13. Retrospective-prospective study of safety and efficacy of sofosbuvir-based direct-acting antivirals in HIV/HCV-coinfected participants with decompensated liver disease pre– or post–liver transplant

Author

Peters, Marion G., Kottilil, Shyam, Terrault, Norah, Amara, Dominic, Husson, Jennifer, Huprikar, Shirish, Florman, Sander, Sulkowski, Mark S., Durand, Christine M., Luetkemeyer, Anne F., Rogers, Rodney, Grab, Joshua, Haydel, Brandy, Blumberg, Emily, Dove, Lorna, Emond, Jean, Olthoff, Kim, Smith, Coleman, Fishbein, Thomas, Masur, Henry, and Stock, Peter G.

Published
2021
Full Text
View/download PDF

15. Improving Sepsis Outcomes in the Era of Pay-for-Performance and Electronic Quality Measures: A Joint IDSA/ACEP/PIDS/SHEA/SHM/SIDP Position Paper

Author

Rhee, Chanu, primary, Strich, Jeffrey R, additional, Chiotos, Kathleen, additional, Classen, David C, additional, Cosgrove, Sara E, additional, Greeno, Ron, additional, Heil, Emily L, additional, Kadri, Sameer S, additional, Kalil, Andre C, additional, Gilbert, David N, additional, Masur, Henry, additional, Septimus, Edward J, additional, Sweeney, Daniel A, additional, Terry, Aisha, additional, Winslow, Dean L, additional, Yealy, Donald M, additional, and Klompas, Michael, additional

Published
2023
Full Text
View/download PDF

16. Lack of Efficacy of High-Titered Immunoglobulin in Patients with West Nile Virus Central Nervous System Disease

Author

Gnann, John W., Jr., Agrawal, Amy, Hart, John, Buitrago, Martha, Carson, Paul, Hanfelt-Goade, Diane, Tyler, Ken, Spotkov, Jared, Freifeld, Alison, Moore, Thomas, Reyno, Jorge, Masur, Henry, Jester, Penelope, Dale, Ilet, Li, Yufeng, Aban, Inmaculada, Lakeman, Fred D., and Whitley, Richard J.

Subjects
Hospital patients -- Care and treatment -- Health aspects, West Nile fever -- Research -- Care and treatment -- Health aspects, Medical research -- Health aspects, Infection -- Research -- Care and treatment -- Health aspects, Nervous system diseases -- Research -- Care and treatment -- Health aspects, Biological products -- Health aspects, Immunoglobulin G -- Health aspects, Morbidity, Immunoglobulins, Antibodies, Central nervous system, Health
Abstract

West Nile virus (WNV) is a mosquitoborne flavivirus that causes a spectrum of human illnesses, ranging from asymptomatic infection to an undifferentiated febrile syndrome (West Nile fever) and potentially lethal [...]

Published
2019
Full Text
View/download PDF

18. Executive Summary: Surviving Sepsis Campaign: International Guidelines for the Management of Sepsis and Septic Shock 2021

Author

Evans, Laura, Rhodes, Andrew, Alhazzani, Waleed, Antonelli, Massimo, Coopersmith, Craig M., French, Craig, Machado, Flávia R., Mcintyre, Lauralyn, Ostermann, Marlies, Prescott, Hallie C., Schorr, Christa, Simpson, Steven, Joost Wiersinga, W., Alshamsi, Fayez, Angus, Derek C., Arabi, Yaseen, Azevedo, Luciano, Beale, Richard, Beilman, Gregory, Belley-Cote, Emilie, Burry, Lisa, Cecconi, Maurizio, Centofanti, John, Yataco, Angel Coz, De Waele, Jan, Dellinger, R. Phillip, Doi, Kent, Du, Bin, Estenssoro, Elisa, Ferrer, Ricard, Gomersall, Charles, Hodgson, Carol, Møller, Morten Hylander, Iwashyna, Theodore, Jacob, Shevin, Kleinpell, Ruth, Klompas, Michael, Koh, Younsuck, Kumar, Anand, Kwizera, Arthur, Lobo, Suzana, Masur, Henry, McGloughlin, Steven, Mehta, Sangeeta, Mehta, Yatin, Mer, Mervyn, Nunnally, Mark, Oczkowski, Simon, Osborn, Tiffany, Papathanassoglou, Elizabeth, Perner, Anders, Puskarich, Michael, Roberts, Jason, Schweickert, William, Seckel, Maureen, Sevransky, Jonathan, Sprung, Charles L., Welte, Tobias, Zimmerman, Janice, and Levy, Mitchell

Published
2021
Full Text
View/download PDF

19. Improving Sepsis Outcomes in the Era of Pay-for-Performance and Electronic Quality Measures: A Joint IDSA/ACEP/PIDS/SHEA/SHM/SIDP Position Paper.

Author

Rhee, Chanu, Strich, Jeffrey R, Chiotos, Kathleen, Classen, David C, Cosgrove, Sara E, Greeno, Ron, Heil, Emily L, Kadri, Sameer S, Kalil, Andre C, Gilbert, David N, Masur, Henry, Septimus, Edward J, Sweeney, Daniel A, Terry, Aisha, Winslow, Dean L, Yealy, Donald M, and Klompas, Michael

Subjects
MORTALITY prevention, MEDICARE, HOSPITAL care, TREATMENT effectiveness, BLOOD plasma substitutes, SEPTIC shock, SEPSIS, LABOR incentives, PAY for performance, COMORBIDITY
Abstract

The Centers for Medicare & Medicaid Services (CMS) introduced the Severe Sepsis/Septic Shock Management Bundle (SEP-1) as a pay-for-reporting measure in 2015 and is now planning to make it a pay-for-performance measure by incorporating it into the Hospital Value-Based Purchasing Program. This joint IDSA/ACEP/PIDS/SHEA/SHM/SIPD position paper highlights concerns with this change. Multiple studies indicate that SEP-1 implementation was associated with increased broad-spectrum antibiotic use, lactate measurements, and aggressive fluid resuscitation for patients with suspected sepsis but not with decreased mortality rates. Increased focus on SEP-1 risks further diverting attention and resources from more effective measures and comprehensive sepsis care. We recommend retiring SEP-1 rather than using it in a payment model and shifting instead to new sepsis metrics that focus on patient outcomes. CMS is developing a community-onset sepsis 30-day mortality electronic clinical quality measure (eCQM) that is an important step in this direction. The eCQM preliminarily identifies sepsis using systemic inflammatory response syndrome (SIRS) criteria, antibiotic administrations or diagnosis codes for infection or sepsis, and clinical indicators of acute organ dysfunction. We support the eCQM but recommend removing SIRS criteria and diagnosis codes to streamline implementation, decrease variability between hospitals, maintain vigilance for patients with sepsis but without SIRS, and avoid promoting antibiotic use in uninfected patients with SIRS. We further advocate for CMS to harmonize the eCQM with the Centers for Disease Control and Prevention's (CDC) Adult Sepsis Event surveillance metric to promote unity in federal measures, decrease reporting burden for hospitals, and facilitate shared prevention initiatives. These steps will result in a more robust measure that will encourage hospitals to pay more attention to the full breadth of sepsis care, stimulate new innovations in diagnosis and treatment, and ultimately bring us closer to our shared goal of improving outcomes for patients. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

22. Drug Resistance in Pneumocystis jirovecii

Author

Helweg-Larsen, Jannik, Benfield, Thomas, Kovacs, Joseph, Masur, Henry, Mayers, Douglas L., editor, Sobel, Jack D., editor, Ouellette, Marc, editor, Kaye, Keith S., editor, and Marchaim, Dror, editor

Published
2017
Full Text
View/download PDF

23. Induced hypothermia in patients with septic shock and respiratory failure (CASS): a randomised, controlled, open-label trial

Author

Jensen, Jens-Ulrik Stæhr, Itenov, Theis Skovsgaard, Johansen, Maria Egede, Lundgren, Jens, Tønnesen, Else, Bestle, Morten, Lindhardt, Anne, Christensen, Henrik, Planck Pedersen, Henrik, Poulsen, Lone Musaeus, Cozzi-Lepri, Alessandro, Illkjær, Susanne, Soni, Uday Kant, Møller, Kirsten, Juffermans, Nicole P, Sessler, Daniel I, Mohr, Thomas, Masur, Henry, Torp-Pedersen, Christian, Copas, Andrew, Nielsen, Birgit Riis, Kristensen, Dennis Karsten, Grarup, Jesper, Hansen, Jette, Nielsen, Kim, Valbjørn, Lone, Lauritzen, Sanne, Kold, Tina, Grundahl, Kathrine, Hein, Lars, Rasmussen, Rikke Hein, Wesche, Nikolaj, Blom, Hasse, Jensen, Peer Eske, Galle, Tina, Thaarslund, Bente, Skandov, Camilla, Langholz, Iben, Skram, Ulrik, Berthelsen, Rasmus Ehrenfried, Kjær, Dorthe, Uldbjerg, Merete, Lipsius, Lily, Gyldensted, Louise, Engsig, Magaly, Helsted, Rikke, Andersen, Birgitte, Nygaard, Eigil, Strande, Søren, Bangash, Aimal Khan, Waldau, Tina, Søe-Jensen, Peter, Tousi, Hamid, Tangager, Malene, Hagi-Pedersen, Daniel, Gatz, Rainer Karl-Heinz, Engen, Marte Kaasen, Wamberg, Christian Åge, Westergaard, Bo, Harmon, Matthew, Thormar, Katrin, Stoktoft, Stine, Scherwin, Rebecca, Bærentzen, Finn, Lauritzen, Marlene, Pott, Frank, Bruun, Christina, Meyhoff, Christian, Strange, Ditte Gry, Palmqvist, Dorthe Fris, Hemmingsen, Claus, Gärtner, Rune, Petersen, John Asger, Jung, Kai Dieter, La Porte, Louise, Viuf, Mette, Troglauer, Johannes, Borovnjak, Silva, Strandkjær, Nina, Bretlau, Claus, Hansen, Marianna, Zaulich, Lea Kielsgaard, Overgaard, Christian, Bergenholtz, Katja, Jansen, Tejs, Bæk-Jensen, Mette Astrup, Detlefsen, Monika, Albrechtsen, Tannie Lund, Sode, Birgitte Margareta, Boesen, Hans Christian, Thostrup, Maria, Estrup, Stine, Andersen, Torben Mogens, Kjelsteen, Katrine, Winther Kjær, Cilia Klara, Haunstrup, Elsebeth, Christensen, Ole, Spliid, Lone, Rasmussen, Birgitte, Jejlskov, Henriette, Borchorst, Søren, Abdel-Wahab, Akil Walli Raad, Brysting, Marianne, Victor, Jette, Stensbirk, Anette, Bjerregaard, Karen, Poulsen, Anne, Roed, Annette Brix, Bech, Bianca, Perez-Protto, Silvia, Yilmaz, Oguz, Ahuja, Sanchit, Suleiman, Iman, Iglesias, Rodrigo, Breum, Olena, Pedersen, Henrik Planck, Wesche, Nicolai, Strange, Ditte, Lundgren, Jens D, and Jensen, Jens-Ulrik

Published
2018
Full Text
View/download PDF

29. Nucleic acid amplification tests for diagnosis of smear-negative TB in a high HIV-prevalence setting: a prospective cohort study.

Author

Davis, J Lucian, Huang, Laurence, Worodria, William, Masur, Henry, Cattamanchi, Adithya, Huber, Charles, Miller, Cecily, Conville, Patricia S, Murray, Patrick, and Kovacs, Joseph A

Subjects
Humans, Mycobacterium tuberculosis, Tuberculosis, HIV Infections, Prevalence, Sensitivity and Specificity, Cohort Studies, Prospective Studies, Nucleic Acid Amplification Techniques, Polymerase Chain Reaction, Comorbidity, Adult, General Science & Technology
Abstract

BackgroundNucleic acid amplification tests are sensitive for identifying Mycobacterium tuberculosis in populations with positive sputum smears for acid-fast bacilli, but less sensitive in sputum-smear-negative populations. Few studies have evaluated the clinical impact of these tests in low-income countries with high burdens of TB and HIV.MethodsWe prospectively enrolled 211 consecutive adults with cough ≥2 weeks and negative sputum smears at Mulago Hospital in Kampala, Uganda. We tested a single early-morning sputum specimen for Mycobacterium tuberculosis DNA using two nucleic acid amplification tests: a novel in-house polymerase chain reaction targeting the mycobacterial secA1 gene, and the commercial Amplified® Mycobacterium tuberculosis Direct (MTD) test (Gen-Probe Inc, San Diego, CA). We calculated the diagnostic accuracy of these index tests in reference to a primary microbiologic gold standard (positive mycobacterial culture of sputum or bronchoalveolar lavage fluid), and measured their likely clinical impact on additional tuberculosis cases detected among those not prescribed initial TB treatment.ResultsOf 211 patients enrolled, 170 (81%) were HIV-seropositive, with median CD4+ T-cell count 78 cells/µL (interquartile range 29-203). Among HIV-seropositive patients, 94 (55%) reported taking co-trimoxazole prophylaxis and 29 (17%) reported taking antiretroviral therapy. Seventy-five patients (36%) had culture-confirmed TB. Sensitivity of MTD was 39% (95% CI 28-51) and that of secA1 was 24% (95% CI 15-35). Both tests had specificities of 95% (95% CI 90-98). The MTD test correctly identified 18 (24%) TB patients not treated at discharge and led to a 72% relative increase in the smear-negative case detection rate.ConclusionsThe secA1 and MTD nucleic acid amplification tests had moderate sensitivity and high specificity for TB in a predominantly HIV-seropositive population with negative sputum smears. Although newer, more sensitive nucleic acid assays may enhance detection of Mycobacterium tuberculosis in sputum, even currently available tests can provide substantial clinical impact in smear-negative populations.

Published
2011

38. HIV-1 and T Cell Dynamics after Interruption of Highly Active Antiretroviral Therapy (HAART) in Patients with a History of Sustained Viral Suppression

Author

Davey,, Richard T., Bhat, Niranjan, Yoder, Christian, Chun, Tae-Wook, Metcalf, Julia A., Dewar, Robin, Natarajan, Ven, Lempicki, Richard A., Adelsberger, Joseph W., Miller, Kirk D., Kovacs, Joseph A., Polis, Michael A., Walker, Robert E., Falloon, Judith, Masur, Henry, Gee, Dennis, Baseler, Michael, Dimitrov, Dimiter S., Fauci, Anthony S., and Lane, H. Clifford

Published
1999

41. Current Epidemiology of Pneumocystis Pneumonia - Volume 10, Number 10—October 2004 - Emerging Infectious Diseases journal - CDC

Author

Morris, Alison, Lundgren, Jens D, Masur, Henry, Walzer, Peter D, Hanson, Debra L, Frederick, Toni, Huang, Laurence, Beard, Charles B, and Kaplan, Jonathan E

Subjects
Medical Microbiology, Biomedical and Clinical Sciences, Clinical Sciences, Infectious Diseases, HIV/AIDS, Pneumonia, Lung, Pneumonia & Influenza, Aetiology, 2.4 Surveillance and distribution, Infection, Good Health and Well Being, AIDS-Related Opportunistic Infections, Acquired Immunodeficiency Syndrome, Adult, Africa, Antiretroviral Therapy, Highly Active, Child, Developed Countries, Developing Countries, Global Health, HIV, Humans, Incidence, Pneumocystis carinii, Pneumonia, Pneumocystis, Risk Factors, Public Health and Health Services, Microbiology, Clinical sciences, Epidemiology, Health services and systems
Abstract

Pneumocystis pneumonia (PCP) has historically been one of the leading causes of disease among persons with AIDS. The introduction of highly active antiretroviral therapy in industrialized nations has brought about dramatic declines in the incidence of AIDS-associated complications, including PCP. In the adult population, the incidence of PCP has significantly decreased, but it remains among the most common AIDS-defining infections. Similar declines have been documented in the pediatric population. In much of the developing world, PCP remains a significant health problem, although its incidence among adults in sub-Saharan Africa has been debated. This review discusses the epidemiology of PCP during the current era of the AIDS epidemic. Although fewer cases of PCP occur in industrialized countries, increasing drug-resistant HIV infections, possible drug-resistant PCP, and the tremendous number of AIDS cases in developing countries make this disease of continued public health importance.

Published
2004

45. Moderate Sustained Virologic Response Rates With 6-Week Combination Directly Acting Anti–Hepatitis C Virus Therapy in Patients With Advanced Liver Disease

Author

Kattakuzhy, Sarah, Wilson, Eleanor, Sidharthan, Sreetha, Sims, Zayani, McLaughlin, Mary, Price, Angie, Silk, Rachel, Gross, Chloe, Akoth, Elizabeth, McManus, Maryellen, Emmanuel, Benjamin, Shrivastava, Shikha, Tang, Lydia, Nelson, Amy, Teferi, Gebeyehu, Chavez, Jose, Lam, Brian, Mo, Hongmei, Osinusi, Anuoluwapo, Polis, Michael A., Masur, Henry, Kohli, Anita, and Kottilil, Shyamasundaran

Published
2016

46. Successful Retreatment of Chronic HCV Genotype-1 Infection With Ledipasvir and Sofosbuvir After Initial Short Course Therapy With Direct-Acting Antiviral Regimens

Author

Wilson, Eleanor M., Kattakuzhy, Sarah, Sidharthan, Sreetha, Sims, Zayani, Tang, Lydia, McLaughlin, Mary, Price, Angie, Nelson, Amy, Silk, Rachel, Gross, Chloe, Akoth, Elizabeth, Mo, Hongmei, Subramanian, G. Mani, Pang, Phillip S., McHutchison, John G., Osinusi, Anu, Masur, Henry, Kohli, Anita, and Kottilil, Shyam

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results